Compare RPD & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RPD | COLL |
|---|---|---|
| Founded | 2000 | 2002 |
| Country | United States | United States |
| Employees | N/A | 423 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 746.5M | 768.2M |
| IPO Year | 2015 | 2015 |
| Metric | RPD | COLL |
|---|---|---|
| Price | $14.44 | $24.78 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 24 | 8 |
| Target Price | $15.50 | ★ $44.00 |
| AVG Volume (30 Days) | ★ 1.9M | 533.8K |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.16 | ★ 0.64 |
| Revenue | $685,083,000.00 | ★ $780,567,000.00 |
| Revenue This Year | N/A | $6.59 |
| Revenue Next Year | N/A | $1.89 |
| P/E Ratio | $95.75 | ★ $39.44 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.97 | $21.43 |
| 52 Week High | $18.56 | $50.79 |
| Indicator | RPD | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 49.55 | 53.68 |
| Support Level | $11.04 | $21.67 |
| Resistance Level | $18.56 | $26.39 |
| Average True Range (ATR) | 1.25 | 0.92 |
| MACD | -0.14 | 0.05 |
| Stochastic Oscillator | 25.25 | 44.20 |
Founded in 2000, Rapid7 is a cybersecurity company that began providing vulnerability management solutions. It has, however, expanded its portfolio to provide extended detection and response; security information and event management; cloud security, threat intelligence, and application security; and security orchestration, automation, and response. The Boston-based company went public in 2015.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.